Download PDF
Erfahrungsheilkunde 2023; 72(04): 211-218
DOI: 10.1055/a-2107-7184
Praxis

Studienevidenz zu Vitamin-C-Infusionen in der Onkologie

Claudia Vollbracht
› Further Information
    Permissions and Reprints

Zusammenfassung

Ein Vitamin-C-Mangel ist bei onkologischen Patientinnen und Patienten häufig und korreliert mit einer verminderten Lebensqualität und einer schlechteren Überlebensrate. Die Infusionsbehandlung kann Mangelzustände schnell beheben. Studien zeigen eine deutliche Verbesserung der Lebensqualität – insbesondere eine signifikante Linderung von Fatigue, Schmerzen, Appetitmangel, Schlafstörungen und Depressionen. Darüber hinaus kommt es unter Vitamin-C-Therapie zu einer geringeren Myelosuppression und einer klinisch relevanten Erhöhung der Lymphozytenzahl bei Lymphopenie. Erste klinische Studiendaten zeigen auch eine verlängerte Überlebenszeit. Letzteres wird durch experimentelle Studien unterstützt, die eine direkte selektive tumorzytotoxische Wirkung über die Bildung von Wasserstoffperoxid, eine Verschiebung des epigenetischen Profils in Richtung Tumorsuppression und eine Abnahme metastasierungsrelevanter Prozesse beobachten.

Abstract

Vitamin C deficiency is common in oncology patients and correlates with a decreased quality of life and a poorer survival rate. Infusion treatments can quickly address these deficiencies, and studies show they bring about a significant improvement in quality of life – particularly notable is the relief of fatigue, pain, appetite loss, sleep disturbances, and depression. Moreover, vitamin C treatment leads to less myelosuppression and a clinically significant increase in the lymphocyte count in cases of lymphopenia. Initial clinical trial data also indicates an extension in survival time. This observation is supported by experimental studies that reveal a direct, selective cytotoxic effect on tumors through the formation of hydrogen peroxide, a shift in the epigenetic profile towards tumor suppression, and a decrease in processes relevant to metastasis.

Schlüsselwörter

Vitamin C - Onkologie - tumorzytotoxische Wirkung - Vitamin-C-Mangel - Vitamin-C-Infusionstherapie

Key words

vitamin C - oncology - tumoricidal effect - vitamin c deficiency - vitamin c infusion therapy


Publication History

Article published online:
10 August 2023

© 2023. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • Literatur

  • 1 Carr AC, Cook J. Intravenous vitamin C for cancer therapy – identifying the current gaps in our knowledge. Front Physiol 2018; 9: 1182
    CrossrefPubMedGoogle Scholar
  • 2 Carr AC, Vissers MC, Cook JS. The effect of intravenous vitamin C on cancer- and chemotherapy-related fatigue and quality of life. Front Oncol 2014; 4: 283
    PubMedGoogle Scholar
  • 3 Mayland CR, Bennett MI, Allan K. Vitamin C deficiency in cancer patients. Palliat Med 2005; 19 (01) 17-20
    CrossrefPubMedGoogle Scholar
  • 4 Campbell EJ, Dachs GU, Morrin HR. et al. Activation of the hypoxia pathway in breast cancer tissue and patient survival are inversely associated with tumor ascorbate levels. BMC Cancer 2019; 19 (01) 307
    CrossrefPubMedGoogle Scholar
  • 5 Blaszczak W, Barczak W, Masternak J. et al. Vitamin C as a modulator of the response to cancer therapy. Molecules 2019 24. 03
    PubMedGoogle Scholar
  • 6 Zhao H, Zhu H, Huang J. et al. The synergy of vitamin C with decitabine activates TET2 in leukemic cells and significantly improves overall survival in elderly patients with acute myeloid leukemia. Leuk Res 2018; 66: 1-7
    CrossrefPubMedGoogle Scholar
  • 7 Ngo B, Van Riper JM, Cantley LC. et al. Targeting cancer vulnerabilities with high-dose vitamin C. Nat Rev Cancer 2019; 19 (05) 271-282
    CrossrefPubMedGoogle Scholar
  • 8 Lee Chong T, Ahearn EL, Cimmino L. Reprogramming the epigenome with vitamin C. Front Cell Dev Biol 2019; 7: 128
    CrossrefPubMedGoogle Scholar
  • 9 Polireddy K, Dong R, Reed G. et al. High dose parenteral ascorbate inhibited pancreatic cancer growth and metastasis: Mechanisms and a phase I/IIa study. Sci Rep 2017; 7 (01) 17188
    CrossrefPubMedGoogle Scholar
  • 10 Vollbracht C, Schneider B, Leendert V. et al. Intravenous vitamin C administration improves quality of life in breast cancer patients during chemo-/radiotherapy and aftercare: Results of a retrospective, multicentre, epidemiological cohort study in Germany. In Vivo 2011; 25 (06) 983-990
    PubMedGoogle Scholar
  • 11 Ou J, Zhu X, Chen P. et al. A randomized phase II trial of best supportive care with or without hyperthermia and vitamin C for heavily pretreated, advanced, refractory non-small-cell lung cancer. J Adv Res 2020; 24: 175-182
    CrossrefPubMedGoogle Scholar
  • 12 Ou J, Zhu X, Zhang H. et al. A retrospective study of gemcitabine and carboplatin with or without intravenous vitamin C on patients with advanced triple-negative breast cancer. Integr Cancer Ther 2020; 19: 1534735419895591
    CrossrefPubMedGoogle Scholar
  • 13 Ou J. et al. A retrospective study of gemcitabine and carboplatin with or without intravenous vitamin C on patients with advanced triple-negative breast cancer. Integr Cancer Ther 2020; 19: 1534735419895591
    CrossrefPubMedGoogle Scholar
  • 14 Rodríguez DM, Guerrero ME, Maldonado BM. et al. Total lymphocyte count in cancer patients with lymphopenia treated with intravenous vitamin C: Results of an observational study. Transl Med Comm 2017; 2 (01) 3
    CrossrefPubMedGoogle Scholar
  • 15 Carr AC, McCall C. The role of vitamin C in the treatment of pain: New insights. J Transl Med 2017; 15 (01) 77
    CrossrefPubMedGoogle Scholar
  • 16 Hung KC, Lin Y-T, Chen K-H. et al. The effect of perioperative vitamin C on postoperative analgesic consumption: A meta-analysis of randomized controlled trials. Nutrients 2020; 12 (10) 3109
    CrossrefPubMedGoogle Scholar
  • 17 Böttger F, Vallés-Martí A, Cahn L. et al. High-dose intravenous vitamin C, a promising multi-targeting agent in the treatment of cancer. J Exp Clin Cancer Res 2021; 40 (01) 343
    CrossrefPubMedGoogle Scholar
  • 18 Lykkesfeldt J. On the effect of vitamin C intake on human health: How to (mis)interprete the clinical evidence. Redox Biol 2020; 34: 101532
    CrossrefPubMedGoogle Scholar
  • 19 Wang F, Ming-Ming H, Xiao J. et al. A randomized, open-label, multicenter, phase 3 study of high-dose vitamin C plus FOLFOX ± bevacizumab versus FOLFOX ± bevacizumab in unresectable untreated metastatic colorectal cancer (VITALITY study). Clin Cancer Res 2022; 28 (19) 4232-4239
    CrossrefPubMedGoogle Scholar
  • 20 Ma Y, Chapman J, Levine M. et al. High-dose parenteral ascorbate enhanced chemosensitivity of ovarian cancer and reduced toxicity of chemotherapy. Sci Transl Med 2014; 6 (222) 222ra18
    PubMedGoogle Scholar
  • 21 Bolaman AZ, Turgutkaya A, Küçükdiler HE. et al. Pharmacological dose ascorbic acid administration in relapsed refractory multiple myeloma patients. Leuk Res Rep 2021; 16: 100281
    PubMedGoogle Scholar
  • 22 Takahashi H, Mizuno H, Yanagisawa A. High-dose intravenous vitamin C improves quality of life in cancer patients. Pers Med Univ 2012; 1: 49-53
    CrossrefPubMedGoogle Scholar
  • 23 Yeom CH, Jung CG, Song KJ. Changes of terminal cancer patients‘ health-related quality of life after high dose vitamin C administration. J Korean Med Sci 2007; 22 (01) 7-11
    CrossrefPubMedGoogle Scholar